New! Sign up for our free email newsletter.
Science News
from research organizations

New Research Provides Hope For Childhood Cancer Sufferers

Date:
July 18, 2007
Source:
Children's Cancer Institute Australia
Summary:
New research provides hope for childhood cancer sufferers. Scientists investigating drug therapies for children with acute lymphoblastic leukaemia have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.
Share:
FULL STORY

New research provides hope for childhood cancer sufferers as a small molecule is shown, for the first time, to increase the effectiveness of standard therapies.

Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.

Dr Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the journal Blood.

ALL is the most common form of childhood cancer. Over the years, improvements in primary therapy have increased the cure rate to approximately 80 percent. However, for the 20 percent of patients who relapse, the majority will die.

"When used in combination with common drugs administered in ALL therapy, ABT-737 has the ability to enhance the combined toxicity of these drugs against the leukaemia cells with minimal effects on the normal cells of the body," said Dr Lock.

Resistance to common therapeutic drugs is associated with poor long-term outcomes in leukaemia patients. In the study, the effects of ABT-737 in combination with three common chemotherapeutic agents: L-Asparaginase, vincristine and dexamethasone, were tested on a number of ALL cell lines under conditions which were considered clinically relevant for the disease.

ABT-737, developed by Abbott Laboratories, acts by inhibiting the Bcl-2 family of proteins. These proteins are expressed in ALL and inhibit the mechanisms responsible for destroying leukaemia cells. High levels of expression of Bcl-2 is linked with chemoresistance in a variety of cancers.

"There is a critical need for new drugs with novel mechanisms of action that might improve the outcome for relapsed ALL patients," said Dr Lock.


Story Source:

Materials provided by Children's Cancer Institute Australia. Note: Content may be edited for style and length.


Cite This Page:

Children's Cancer Institute Australia. "New Research Provides Hope For Childhood Cancer Sufferers." ScienceDaily. ScienceDaily, 18 July 2007. <www.sciencedaily.com/releases/2007/07/070716132614.htm>.
Children's Cancer Institute Australia. (2007, July 18). New Research Provides Hope For Childhood Cancer Sufferers. ScienceDaily. Retrieved March 29, 2024 from www.sciencedaily.com/releases/2007/07/070716132614.htm
Children's Cancer Institute Australia. "New Research Provides Hope For Childhood Cancer Sufferers." ScienceDaily. www.sciencedaily.com/releases/2007/07/070716132614.htm (accessed March 29, 2024).

Explore More

from ScienceDaily

RELATED STORIES